Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acumen Pharmaceuticals, Inc. (ABOS)

3.92   -0.06 (-1.51%) 03-24 11:58
Open: 4.05 Pre. Close: 3.98
High: 4.02 Low: 3.8298
Volume: 19,878 Market Cap: 160(M)

Technical analysis

as of: 2023-03-24 10:41:25 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.97     One year: 6.97
Support: Support1: 3.74    Support2: 3.11
Resistance: Resistance1: 5.11    Resistance2: 5.96
Pivot: 4.43
Moving Average: MA(5): 3.92     MA(20): 4.62
MA(100): 5.59     MA(250): 5.37
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 12.7     %D(3): 10.9
RSI: RSI(14): 30.6
52-week: High: 10.97  Low: 3.01
Average Vol(K): 3-Month: 80 (K)  10-Days: 121 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABOS ] has closed above bottom band by 29.8%. Bollinger Bands are 91.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.26 - 4.29 4.29 - 4.31
Low: 3.79 - 3.81 3.81 - 3.83
Close: 3.94 - 3.98 3.98 - 4.02

Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Headline News

Thu, 16 Mar 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat

Sat, 11 Mar 2023
Moore Capital Management LP buys 64,420 Acumen ... - Best Stocks

Fri, 10 Mar 2023
Moore Capital Management LP Acquires 64420 Shares of Acumen ... - MarketBeat

Wed, 08 Mar 2023
Acumen Pharmaceuticals to Participate in the Needham ... - InvestorsObserver

Mon, 13 Feb 2023
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ... - GlobeNewswire

Wed, 04 Jan 2023
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 41 (M)
Shares Float 14 (M)
% Held by Insiders 15.5 (%)
% Held by Institutions 74.3 (%)
Shares Short 634 (K)
Shares Short P.Month 610 (K)

Stock Financials

EPS 1.11
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.86
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -11.3
Return on Equity (ttm) -17.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.31
Sales Per Share 0
EBITDA (p.s.) -0.97
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio 3.53
PEG Ratio -0.5
Price to Book value 0.8
Price to Sales 0
Price to Cash Flow -5.83

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.